Harrow Health, Inc. (NASDAQ: HROW) Stock Competitors & Peer Comparison
See HROW's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HROW and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HROW | $40.04 | +0.31% | 1.5B | 449.33 | $0.09 | N/A |
| TAK | $17.52 | +2.94% | 55.5B | 12.55 | $1.39 | +3.61% |
| HLN | $9.93 | -1.05% | 44.2B | 25.11 | $0.40 | +1.76% |
| TEVA | $35.42 | +1.75% | 41.2B | 12.06 | $2.93 | N/A |
| VTRS | $16.27 | -0.12% | 19.1B | 6.52 | $2.52 | +2.90% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.07 | -8.80% | 11B | 20.86 | $1.06 | N/A |
| RDY | $12.07 | -0.37% | 10.2B | 20.01 | $0.61 | +0.68% |
| LNTH | $100.89 | -0.18% | 6.6B | 16.97 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
HROW vs TAK Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, TAK has a market cap of 55.5B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while TAK trades at $17.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas TAK's P/E ratio is 12.55. In terms of profitability, HROW's ROE is -0.34%, compared to TAK's ROE of +0.02%. Regarding short-term risk, HROW is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for HROW.Check TAK's competition here
Haleon plc (NYSE: HLN)
HROW vs HLN Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, HLN has a market cap of 44.2B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while HLN trades at $9.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas HLN's P/E ratio is 25.11. In terms of profitability, HROW's ROE is -0.34%, compared to HLN's ROE of +0.17%. Regarding short-term risk, HROW is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for HROW.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
HROW vs TEVA Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, TEVA has a market cap of 41.2B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while TEVA trades at $35.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas TEVA's P/E ratio is 12.06. In terms of profitability, HROW's ROE is -0.34%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, HROW is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for HROW.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
HROW vs VTRS Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, VTRS has a market cap of 19.1B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while VTRS trades at $16.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas VTRS's P/E ratio is 6.52. In terms of profitability, HROW's ROE is -0.34%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, HROW is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for HROW.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
HROW vs ITCI Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ITCI's P/E ratio is -180.64. In terms of profitability, HROW's ROE is -0.34%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, HROW is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for HROW.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
HROW vs CTLT Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas CTLT's P/E ratio is -27.84. In terms of profitability, HROW's ROE is -0.34%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, HROW is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for HROW.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
HROW vs ELAN Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ELAN has a market cap of 11B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ELAN trades at $22.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ELAN's P/E ratio is 20.86. In terms of profitability, HROW's ROE is -0.34%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, HROW is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for HROW.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
HROW vs RDY Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while RDY trades at $12.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas RDY's P/E ratio is 20.01. In terms of profitability, HROW's ROE is -0.34%, compared to RDY's ROE of +0.09%. Regarding short-term risk, HROW is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for HROW.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
HROW vs LNTH Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while LNTH trades at $100.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas LNTH's P/E ratio is 16.97. In terms of profitability, HROW's ROE is -0.34%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, HROW is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for HROW.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
HROW vs AMRX Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, AMRX has a market cap of 5.8B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while AMRX trades at $17.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas AMRX's P/E ratio is 20.16. In terms of profitability, HROW's ROE is -0.34%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, HROW is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for HROW.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
HROW vs INDV Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while INDV trades at $38.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas INDV's P/E ratio is 10.64. In terms of profitability, HROW's ROE is -0.34%, compared to INDV's ROE of -2.16%. Regarding short-term risk, HROW is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for HROW.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
HROW vs SUPN Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while SUPN trades at $46.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas SUPN's P/E ratio is 15.57. In terms of profitability, HROW's ROE is -0.34%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, HROW is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for HROW.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
HROW vs RGC Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while RGC trades at $5.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas RGC's P/E ratio is -380.99. In terms of profitability, HROW's ROE is -0.34%, compared to RGC's ROE of -2.32%. Regarding short-term risk, HROW is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for HROW.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
HROW vs BHC Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while BHC trades at $6.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas BHC's P/E ratio is 1.59. In terms of profitability, HROW's ROE is -0.34%, compared to BHC's ROE of +0.89%. Regarding short-term risk, HROW is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for HROW.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
HROW vs DCPH Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas DCPH's P/E ratio is -11.58. In terms of profitability, HROW's ROE is -0.34%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, HROW is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for HROW.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
HROW vs HCM Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while HCM trades at $12.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas HCM's P/E ratio is 4.69. In terms of profitability, HROW's ROE is -0.34%, compared to HCM's ROE of +0.01%. Regarding short-term risk, HROW is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for HROW.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
HROW vs AVDL Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, HROW's ROE is -0.34%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, HROW is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for HROW.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
HROW vs EMBCV Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas EMBCV's P/E ratio is N/A. In terms of profitability, HROW's ROE is -0.34%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, HROW is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for HROW.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
HROW vs DVAX Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas DVAX's P/E ratio is -41.89. In terms of profitability, HROW's ROE is -0.34%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, HROW is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for HROW.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
HROW vs ANIP Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ANIP trades at $75.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ANIP's P/E ratio is 9.52. In terms of profitability, HROW's ROE is -0.34%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, HROW is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for HROW.Check ANIP's competition here
Perrigo Company plc (NYSE: PRGO)
HROW vs PRGO Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while PRGO trades at $12.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas PRGO's P/E ratio is 5.13. In terms of profitability, HROW's ROE is -0.34%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, HROW is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for HROW.Check PRGO's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
HROW vs TARO Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas TARO's P/E ratio is 30.05. In terms of profitability, HROW's ROE is -0.34%, compared to TARO's ROE of +0.03%. Regarding short-term risk, HROW is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for HROW.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
HROW vs PAHC Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while PAHC trades at $34.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas PAHC's P/E ratio is 11.70. In terms of profitability, HROW's ROE is -0.34%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, HROW is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for HROW.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
HROW vs ALVO Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ALVO trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ALVO's P/E ratio is -11.21. In terms of profitability, HROW's ROE is -0.34%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, HROW is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for HROW.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
HROW vs ETON Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ETON trades at $43.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ETON's P/E ratio is -637.14. In terms of profitability, HROW's ROE is -0.34%, compared to ETON's ROE of -0.06%. Regarding short-term risk, HROW is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for HROW.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
HROW vs CRON Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while CRON trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas CRON's P/E ratio is 29.44. In terms of profitability, HROW's ROE is -0.34%, compared to CRON's ROE of +0.06%. Regarding short-term risk, HROW is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for HROW.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
HROW vs PCRX Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, PCRX has a market cap of 984.2M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while PCRX trades at $24.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas PCRX's P/E ratio is 9.62. In terms of profitability, HROW's ROE is -0.34%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, HROW is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for HROW.Check PCRX's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
HROW vs COLL Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, COLL has a market cap of 955.8M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while COLL trades at $27.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas COLL's P/E ratio is 3.70. In terms of profitability, HROW's ROE is -0.34%, compared to COLL's ROE of +0.16%. Regarding short-term risk, HROW is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for HROW.Check COLL's competition here
PetIQ, Inc. (NASDAQ: PETQ)
HROW vs PETQ Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas PETQ's P/E ratio is 83.73. In terms of profitability, HROW's ROE is -0.34%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, HROW is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for HROW.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
HROW vs AMPH Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, AMPH has a market cap of 916.3M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while AMPH trades at $19.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas AMPH's P/E ratio is 7.09. In terms of profitability, HROW's ROE is -0.34%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, HROW is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for HROW.Check AMPH's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
HROW vs IRWD Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while IRWD trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas IRWD's P/E ratio is 5.54. In terms of profitability, HROW's ROE is -0.34%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, HROW is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for HROW.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
HROW vs EVO Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, EVO has a market cap of 710.5M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while EVO trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas EVO's P/E ratio is -2.82. In terms of profitability, HROW's ROE is -0.34%, compared to EVO's ROE of -0.24%. Regarding short-term risk, HROW is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for HROW.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
HROW vs BDSI Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas BDSI's P/E ratio is 6.82. In terms of profitability, HROW's ROE is -0.34%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, HROW is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for HROW.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
HROW vs TLRY Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, TLRY has a market cap of 511.1M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while TLRY trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas TLRY's P/E ratio is -7.21. In terms of profitability, HROW's ROE is -0.34%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, HROW is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for HROW.Check TLRY's competition here
Evolus, Inc. (NASDAQ: EOLS)
HROW vs EOLS Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, EOLS has a market cap of 499.8M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while EOLS trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas EOLS's P/E ratio is -24.04. In terms of profitability, HROW's ROE is -0.34%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, HROW is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for HROW.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
HROW vs AQST Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, AQST has a market cap of 494.3M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while AQST trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas AQST's P/E ratio is -6.46. In terms of profitability, HROW's ROE is -0.34%, compared to AQST's ROE of +1.91%. Regarding short-term risk, HROW is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for HROW.Check AQST's competition here
Kamada Ltd. (NASDAQ: KMDA)
HROW vs KMDA Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, KMDA has a market cap of 419.4M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while KMDA trades at $7.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas KMDA's P/E ratio is 20.77. In terms of profitability, HROW's ROE is -0.34%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, HROW is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for HROW.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
HROW vs CGC Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, CGC has a market cap of 409.5M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while CGC trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas CGC's P/E ratio is -0.58. In terms of profitability, HROW's ROE is -0.34%, compared to CGC's ROE of -0.31%. Regarding short-term risk, HROW is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for HROW.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
HROW vs TKNO Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, TKNO has a market cap of 346.3M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while TKNO trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas TKNO's P/E ratio is -20.84. In terms of profitability, HROW's ROE is -0.34%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, HROW is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for HROW.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
HROW vs ALIM Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ALIM's P/E ratio is 5.28. In terms of profitability, HROW's ROE is -0.34%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, HROW is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for HROW.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
HROW vs LNDC Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas LNDC's P/E ratio is -4.04. In terms of profitability, HROW's ROE is -0.34%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, HROW is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for HROW.Check LNDC's competition here
Embecta Corp. (NASDAQ: EMBC)
HROW vs EMBC Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, EMBC has a market cap of 262.2M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while EMBC trades at $4.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas EMBC's P/E ratio is 1.70. In terms of profitability, HROW's ROE is -0.34%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, HROW is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for HROW.Check EMBC's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
HROW vs ORGO Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ORGO has a market cap of 239.3M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ORGO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ORGO's P/E ratio is 62.00. In terms of profitability, HROW's ROE is -0.34%, compared to ORGO's ROE of -0.27%. Regarding short-term risk, HROW is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for HROW.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
HROW vs TYHT Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas TYHT's P/E ratio is -1.61. In terms of profitability, HROW's ROE is -0.34%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, HROW is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for HROW.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
HROW vs SIGA Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, SIGA has a market cap of 218.8M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while SIGA trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas SIGA's P/E ratio is 11.30. In terms of profitability, HROW's ROE is -0.34%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, HROW is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for HROW.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
HROW vs LFCR Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, LFCR has a market cap of 187.9M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while LFCR trades at $4.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas LFCR's P/E ratio is -4.68. In terms of profitability, HROW's ROE is -0.34%, compared to LFCR's ROE of -1.95%. Regarding short-term risk, HROW is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for HROW.Check LFCR's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
HROW vs ACB Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ACB has a market cap of 185.2M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ACB trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ACB's P/E ratio is -6.10. In terms of profitability, HROW's ROE is -0.34%, compared to ACB's ROE of -0.21%. Regarding short-term risk, HROW is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for HROW.Check ACB's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
HROW vs REPH Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas REPH's P/E ratio is -8.04. In terms of profitability, HROW's ROE is -0.34%, compared to REPH's ROE of -0.22%. Regarding short-term risk, HROW is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for HROW.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
HROW vs DERM Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while DERM trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas DERM's P/E ratio is -17.38. In terms of profitability, HROW's ROE is -0.34%, compared to DERM's ROE of -0.36%. Regarding short-term risk, HROW is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for HROW.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
HROW vs CRDL Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, CRDL has a market cap of 163.7M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while CRDL trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas CRDL's P/E ratio is -5.05. In terms of profitability, HROW's ROE is -0.34%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, HROW is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for HROW.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
HROW vs THTX Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas THTX's P/E ratio is -28.83. In terms of profitability, HROW's ROE is -0.34%, compared to THTX's ROE of +0.17%. Regarding short-term risk, HROW is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for HROW.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
HROW vs ASRT Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ASRT's P/E ratio is -7.10. In terms of profitability, HROW's ROE is -0.34%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, HROW is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for HROW.Check ASRT's competition here
Organigram Global Inc. (NASDAQ: OGI)
HROW vs OGI Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, OGI has a market cap of 139.4M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while OGI trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas OGI's P/E ratio is -3.81. In terms of profitability, HROW's ROE is -0.34%, compared to OGI's ROE of -0.07%. Regarding short-term risk, HROW is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for HROW.Check OGI's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
HROW vs CPIX Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, CPIX has a market cap of 116.9M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while CPIX trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas CPIX's P/E ratio is -19.50. In terms of profitability, HROW's ROE is -0.34%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, HROW is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for HROW.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
HROW vs SCTL Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas SCTL's P/E ratio is -7.86. In terms of profitability, HROW's ROE is -0.34%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, HROW is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for HROW.Check SCTL's competition here
Procaps Group S.A. (NASDAQ: PROC)
HROW vs PROC Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas PROC's P/E ratio is 1.53. In terms of profitability, HROW's ROE is -0.34%, compared to PROC's ROE of -2.22%. Regarding short-term risk, HROW is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for HROW.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
HROW vs OPTN Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas OPTN's P/E ratio is -4.42. In terms of profitability, HROW's ROE is -0.34%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, HROW is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for HROW.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
HROW vs ZOM Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ZOM's P/E ratio is -1.62. In terms of profitability, HROW's ROE is -0.34%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, HROW is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for HROW.Check ZOM's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
HROW vs ZYBT Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ZYBT has a market cap of 89.6M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ZYBT trades at $1.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ZYBT's P/E ratio is -8.59. In terms of profitability, HROW's ROE is -0.34%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, HROW is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for HROW.Check ZYBT's competition here
Upexi, Inc. (NASDAQ: GRVI)
HROW vs GRVI Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas GRVI's P/E ratio is 26.05. In terms of profitability, HROW's ROE is -0.34%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, HROW is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for HROW.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
HROW vs ZYNE Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, HROW's ROE is -0.34%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, HROW is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for HROW.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
HROW vs SSIC Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas SSIC's P/E ratio is 11.93. In terms of profitability, HROW's ROE is -0.34%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, HROW is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for HROW.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
HROW vs VLNS Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas VLNS's P/E ratio is -1.03. In terms of profitability, HROW's ROE is -0.34%, compared to VLNS's ROE of N/A. Regarding short-term risk, HROW is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for HROW.Check VLNS's competition here
BGM Group Ltd. (NASDAQ: BGM)
HROW vs BGM Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, BGM has a market cap of 60.3M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas BGM's P/E ratio is -1.04. In terms of profitability, HROW's ROE is -0.34%, compared to BGM's ROE of -0.07%. Regarding short-term risk, HROW is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for HROW.Check BGM's competition here
DURECT Corporation (NASDAQ: DRRX)
HROW vs DRRX Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas DRRX's P/E ratio is -4.44. In terms of profitability, HROW's ROE is -0.34%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, HROW is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for HROW.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
HROW vs INCR Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, INCR has a market cap of 58M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while INCR trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas INCR's P/E ratio is -2.26. In terms of profitability, HROW's ROE is -0.34%, compared to INCR's ROE of -0.09%. Regarding short-term risk, HROW is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for HROW.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
HROW vs JUPW Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas JUPW's P/E ratio is -2.41. In terms of profitability, HROW's ROE is -0.34%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, HROW is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for HROW.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
HROW vs QLI Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas QLI's P/E ratio is -4.92. In terms of profitability, HROW's ROE is -0.34%, compared to QLI's ROE of -0.16%. Regarding short-term risk, HROW is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for HROW.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
HROW vs HEXO Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas HEXO's P/E ratio is -0.26. In terms of profitability, HROW's ROE is -0.34%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, HROW is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for HROW.Check HEXO's competition here
Talphera, Inc. (NASDAQ: TLPH)
HROW vs TLPH Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, TLPH has a market cap of 29.3M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while TLPH trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas TLPH's P/E ratio is -4.61. In terms of profitability, HROW's ROE is -0.34%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, HROW is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for HROW.Check TLPH's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
HROW vs RMTI Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, RMTI has a market cap of 28.5M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while RMTI trades at $6.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas RMTI's P/E ratio is -6.89. In terms of profitability, HROW's ROE is -0.34%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, HROW is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for HROW.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
HROW vs AYTU Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while AYTU trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas AYTU's P/E ratio is -1.23. In terms of profitability, HROW's ROE is -0.34%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, HROW is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for HROW.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
HROW vs TXMD Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while TXMD trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas TXMD's P/E ratio is 105.45. In terms of profitability, HROW's ROE is -0.34%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, HROW is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for HROW.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
HROW vs CYTH Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas CYTH's P/E ratio is -0.80. In terms of profitability, HROW's ROE is -0.34%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, HROW is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for HROW.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
HROW vs EVOK Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas EVOK's P/E ratio is -7.97. In terms of profitability, HROW's ROE is -0.34%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, HROW is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for HROW.Check EVOK's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
HROW vs BFRIW Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, BFRIW has a market cap of 17M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, HROW's ROE is -0.34%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, HROW is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for HROW.Check BFRIW's competition here
Optimi Health Corp. (NASDAQ: OPTH)
HROW vs OPTH Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, OPTH has a market cap of 16.3M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while OPTH trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas OPTH's P/E ratio is -18.56. In terms of profitability, HROW's ROE is -0.34%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, HROW is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for HROW.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
HROW vs ACRX Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ACRX's P/E ratio is -0.31. In terms of profitability, HROW's ROE is -0.34%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, HROW is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for HROW.Check ACRX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
HROW vs COSM Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, COSM has a market cap of 12.7M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while COSM trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas COSM's P/E ratio is -0.38. In terms of profitability, HROW's ROE is -0.34%, compared to COSM's ROE of -0.96%. Regarding short-term risk, HROW is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for HROW.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
HROW vs AGRX Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas AGRX's P/E ratio is -0.89. In terms of profitability, HROW's ROE is -0.34%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, HROW is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for HROW.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
HROW vs NLTX Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas NLTX's P/E ratio is -0.28. In terms of profitability, HROW's ROE is -0.34%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, HROW is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for HROW.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
HROW vs LCI Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas LCI's P/E ratio is -0.04. In terms of profitability, HROW's ROE is -0.34%, compared to LCI's ROE of +1.66%. Regarding short-term risk, HROW is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for HROW.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
HROW vs ADMP Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ADMP's P/E ratio is -0.08. In terms of profitability, HROW's ROE is -0.34%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, HROW is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for HROW.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
HROW vs YCBD Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, YCBD has a market cap of 5.9M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas YCBD's P/E ratio is -1.38. In terms of profitability, HROW's ROE is -0.34%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, HROW is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for HROW.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
HROW vs GELS Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, GELS has a market cap of 5M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while GELS trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas GELS's P/E ratio is -1.09. In terms of profitability, HROW's ROE is -0.34%, compared to GELS's ROE of -0.25%. Regarding short-term risk, HROW is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for HROW.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
HROW vs MNK Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas MNK's P/E ratio is -0.44. In terms of profitability, HROW's ROE is -0.34%, compared to MNK's ROE of -0.26%. Regarding short-term risk, HROW is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for HROW.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
HROW vs FLGC Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas FLGC's P/E ratio is -0.19. In terms of profitability, HROW's ROE is -0.34%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, HROW is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for HROW.Check FLGC's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
HROW vs CPHI Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, CPHI has a market cap of 3.6M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while CPHI trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas CPHI's P/E ratio is -1.76. In terms of profitability, HROW's ROE is -0.34%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, HROW is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for HROW.Check CPHI's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
HROW vs UPC Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, UPC has a market cap of 3.5M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while UPC trades at $5.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas UPC's P/E ratio is -0.69. In terms of profitability, HROW's ROE is -0.34%, compared to UPC's ROE of -0.03%. Regarding short-term risk, HROW is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for HROW.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
HROW vs SBFM Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while SBFM trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas SBFM's P/E ratio is -0.20. In terms of profitability, HROW's ROE is -0.34%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, HROW is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for HROW.Check SBFM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
HROW vs SHPH Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, SHPH has a market cap of 2.6M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while SHPH trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas SHPH's P/E ratio is -0.20. In terms of profitability, HROW's ROE is -0.34%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, HROW is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for HROW.Check SHPH's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
HROW vs PLXP Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas PLXP's P/E ratio is -0.22. In terms of profitability, HROW's ROE is -0.34%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, HROW is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for HROW.Check PLXP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
HROW vs SNOA Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, SNOA has a market cap of 2.4M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while SNOA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas SNOA's P/E ratio is -1.22. In terms of profitability, HROW's ROE is -0.34%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, HROW is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for HROW.Check SNOA's competition here
Athenex, Inc. (NASDAQ: ATNX)
HROW vs ATNX Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas ATNX's P/E ratio is -0.02. In terms of profitability, HROW's ROE is -0.34%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, HROW is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for HROW.Check ATNX's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
HROW vs PROCW Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas PROCW's P/E ratio is N/A. In terms of profitability, HROW's ROE is -0.34%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, HROW is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for HROW.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
HROW vs RDHL Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while RDHL trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas RDHL's P/E ratio is 0.12. In terms of profitability, HROW's ROE is -0.34%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, HROW is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for HROW.Check RDHL's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
HROW vs YCBD-PA Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, HROW's ROE is -0.34%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, HROW is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for HROW.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
HROW vs CYTHW Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas CYTHW's P/E ratio is N/A. In terms of profitability, HROW's ROE is -0.34%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, HROW is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for HROW.Check CYTHW's competition here
Lucy Scientific Discovery Inc. (NASDAQ: LSDI)
HROW vs LSDI Comparison August 2026
Harrow Health, Inc. (NASDAQ: HROW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROW stands at 1.5B. In comparison, LSDI has a market cap of 906.9K. Regarding current trading prices, HROW is priced at $40.04 on the NASDAQ, while LSDI trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROW currently has a P/E ratio of 449.33, whereas LSDI's P/E ratio is -0.07. In terms of profitability, HROW's ROE is -0.34%, compared to LSDI's ROE of +181.47%. Regarding short-term risk, HROW is less volatile compared to LSDI. This indicates lower risk in terms of short-term price fluctuations for HROW.Check LSDI's competition here